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Background: Esophageal squamous cell carcinoma (ESCC) is the major histological type of esophageal cancer in
developing countries. The prognosis and survival rate of ESCC are very poor. Recently, microRNAs (miRNAs) have
emerged as important regulators of cancer cell biological processes. To better understanding the molecular
mechanisms by which they regulate the behavior of cancer cells is needed.
Methods: The expression of miR-208 was examined in ESCC cell lines and tumor tissues by real-time PCR. Proliferation
capability of ESCC cells upon regulation of miR-208 expression was detected by MTT assay, colony formation assay,
anchorage-independent growth ability assay and flow cytometry analysis. The target of miR-208 was determined by
western blotting analysis, luciferase reporter assay and real-time PCR.
Results: miR-208 was upregulated in ESCC cell lines and tissues. Overexpression of miR-208 in ESCC cells increased cell
proliferation, tumorigenicity and cell cycle progression, whereas inhibition of miR-208 reduced cells proliferation,
tumorigenicity and cell cycle progression. Additionally, SOX6 was identified as a direct target of miR-208. Ectopic
expression of miR-208 led to downregulation of SOX6 protein, which resulted in the downregulation of p21, upregulation
of cyclin D1 and phosphorylation of Rb.
Conclusions: These results suggest that miR-208 represents a potential onco-miR and participates in ESCC
carcinogenesis by suppressing SOX6 expression.
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Esophageal cancer, one of the most common malignant
tumors, is the eighth most common cancer and the sixth
most common causes of cancer mortality in the world
[1]. According to its pathological characteristics, it has
two main subtypes, ESCC and esophageal adenocarcinoma
(EAC) [1,2]. ESCC is the major histological type of esopha-
geal cancer in developing countries [3]. Although advances
have been made in the treatment of ESCC, including sur-
gery, chemotherapy, radiation or a combination of these* Correspondence: ygzihu@163.com; Jianyongyang0899@hotmail.com
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unless otherwise stated.options, the prognosis of ESCC patients remains very
poor, which the overall 5-year survival rate of patient
after surgery is only about 14-22% [3,4]. Some oncogenic
and tumor suppressive factors have been reported to be
associated with ESCC progression; however, few of them
were specific and conclusive [5,6]. Further information on
the biological behavior involved in esophageal cancer initi-
ation and progression, especially in ESCC, is important
for the development of effective diagnostic methods and
therapeutic strategies.
MiRNAs, a class of small non-coding RNAs of 20–22
nucleotides, are involved in multiple biological processes,
such as cell differentiation, proliferation, oncogenesis, angio-
genesis and cell invasion [7-9]. MiRNAs play essential roles
during human cancer progression by targeting the 3′ un-
translated region (3′-UTR) of mRNAs in a sequence-specifichis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Li et al. Journal of Translational Medicine 2014, 12:196 Page 2 of 9
http://www.translational-medicine.com/content/12/1/196manner for translational repression or degradation [10,11].
In view of the close relationship between miRNAs and the
biological progression of multiple cancers, miRNAs are
presently considered as potential novel targets for anti-
cancer therapies [9-12].
SOX6, a member of the D sub family of the sex determi-
ning region Y (SRY)-box-related transcription factors, con-
tains a conserved high-mobility-group (HMG) DNA-binding
domain and plays important roles in biological progression
[13,14]. SOX6 has been reported to play a tumor-suppressive
function in certain tumors. It is frequently downregulated
and significantly associated with better prognosis in primary
ESCC and hepatocellular carcinoma [15,16].
In this study, we found that miR-208 is upregulated in
ESCC cell lines and tissues. We verified a functional role
for miR-208 in ESCC cell proliferation, tumorigenicity
and cell cycle regulation. Furthermore, our data indicated
that SOX6 mRNA is a target of miR-208 and that SOX6 is
essential for the regulation of miR-208 in ESCC cells
in vitro. Our results suggest that miR-208 may promote
cell proliferation, tumorigenicity and cell cycle progression
in ESCC through the SOX6-mediated signaling pathway.
Material and methods
Cell culture
Primary culture of normal esophageal epithelial cells (NEEC)
was established from fresh specimens of the adjacent non-
cancerous esophageal tissue, which is over 5 cm from the
cancerous tissue, according to a previous report [17]. The
ESCC cell lines, including Kyse140, Kyse30, Kyse510,
Kyse520, Eca109, TE-1, Kyse410, Kyse180, EC18, HKESC1
and 108CA, were grown in the Dulbecco’s modified
Eagle’s medium (DMEM, Invitrogen, Carlsbad, CA,
USA) supplemented with 10% fetal bovine serum (FBS)
(HyClone, Logan, UT, USA), 100 units of penicillin and
100 units of streptomycin at 37°C in a 5% CO2 atmos-
phere in a humidified incubator.
Tissue specimens
For the use of the clinical materials for research pur-
poses, prior patient consent and approval from the Insti-
tutional Research Ethics Committee were obtained. This
study was conducted on 10 pairs of snap-frozen ESCC
tumor and matched normal tissues from adjacent
regions, which were histopathologically diagnosed at the
First Affiliated Hospital of Sun Yat-sen University from
2001 to 2006. The 10 ESCC tissues and the matched
adjacent noncancerous esophageal tissues were frozen
and stored in liquid nitrogen until further use.
Generation of stably engineered cell lines
The miR-208 expression plasmid was generated by clon-
ing the genomic pre-miR-208 gene, with 300-bp on each
flanking side, into retroviral transfer plasmid pMSCV-puro(Clontech Laboratories Inc., Moutain View, CA, USA) to
generate plasmid pMSCV-miR-208. The non-targeting
control microRNA (negative control mimic), which are
designed computationally to have no perfect seed-sequence
matches to the transcriptome, was subcloned into retroviral
transfer plasmid pMSCV to generate the plasmid pMSCV-
NC. pMSCV-miR-208 or pMSCV-NC was cotransfected
with the PIK packaging plasmid into 293FT cells using the
standard calcium phosphate transfection method [18].
Thirty-six hours after cotransfection, supernatants were
collected and incubated with cells to be infected for
24 hours in the presence of polybrene (2.5 μg/ml). After
infection, puromycin (1.5 μg/ml) was used to select stably
transduced cells over a 10-day period.
RNA extraction, reverse transcription (RT) and real-time PCR
Total cellular RNA was extracted using the Trizol reagent
(Invitrogen, Carlsbad, CA, USA) according to the manu-
facturer’s instruction. cDNAs were amplified and quanti-
fied in an ABI Prism 7500 Sequence Detection System
(Applied Biosystems, Foster City, CA, USA) using dye
SYBR Green I (Molecular Probes, Invitrogen). The primers
selected were as follows:
p21 forward: 5′-CATGGGTTCTGACGGACAT -3′,
p21 reverse: 5′- AGTCAGTTCCTTGTGGAGCC -3′;
Cyclin D1 forward: 5′-AACTACCTGGACCGCTTCCT -3′,
Cyclin D1 reverse: 5′-CCACTT GAGCTTGTTCACCA-3′.
Expression levels of genes were normalized to that of
the housekeeping gene GAPDH as the control (GAPDH
forward primer, 5′-GACTCATGACCACAGTCCA TGC-3′;
reverse primer, 3′-AGAGGCAGGGATGATGTTCTG-5′),
and calculated as 2-[(Ct of p21, CyclinD1) – (Ct of GAPDH)], where
Ct represents the threshold cycle for each transcript.
The expression of the miRNA was defined based on the
threshold cycle (Ct), and relative expression levels were
calculated as 2-[(Ct of miR-208) – (Ct of U6)] after normalization
with reference to expression of U6 small nuclear RNA.
Western blotting
Western blotting analysis was performed according to
standard methods, as previously described [19]. The mem-
branes were probed with polyclonal rabbit antibodies
against anti-SOX6 (1:500; Abcam, Cambridge, MA, USA),
anti-p21, anti-cyclinD1 and anti-Rb, anti-phosphorylated
Rb (1:1,000; Cell Signaling, Danvers, MA, USA). The mem-
branes were stripped and re-probed with an anti-α-Tubulin
mouse monoclonal antibody (1:1,000; Sigma, Saint Louis,
MO, USA) as a loading control.
Plasmid, oligonucleotides, siRNA and transfection
The region of the human SOX6 3′-UTR, from 1 to
1100 bp, generated by PCR amplification from DNA of
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Madison, WI, USA). The primers selected were as follows:
SOX6-3′UTR-wt-up: 5′- GCCCCGCGGTGGCTCCACA
ATTACATCAGC -3′, SOX6-3′UTR-wt-dn: 3′- GCCCT
GCAGCATAAAATCACTATGTACACAGGA -5′. The
miR-208 mimic, miR-208 inhibitor and negative control
(NC) were purchased from RiboBio (RiboBio Co. Ltd,
Guangzhou, Guangdong, China). For depletion of SOX6,
the siRNA was synthesized and purified by RiboBio. The
SOX6 siRNA sequences used were: CGGGAAACTGTCC
TCCATAAA. Transfection of oligonucleotides and siRNA
were performed using the Lipofectamine 2000 reagent
(Invitrogen, Carlsbad, CA) according to the manufac-
turer’s instruction.
Luciferase assay
ESCC cells (3.5 × 104) were seeded in triplicate in 24-well
plates and allowed to settle for 12 h. One hundred nano-
grams of pGL3-SOX6-luciferase plasmid was transfected
into ESCC cells using the Lipofectamine 2000 reagent
(Invitrogen). Medium was replaced after 6 h, and lucif-
erase and renilla signals were measured 48 h after trans-
fection using the Dual Luciferase Reporter Assay Kit
(Promega) according to the manufacturer’s protocol.
Three independent experiments were performed and
the data were presented as the mean ± SD.
3-(4, 5-Dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium
bromide (MTT) assay
Kyse30 and Kyse410 cells, seeded on 96-well plates, were
stained at the indicated time points with 100 μl sterile
MTT dye (0.5 mg/ml, Sigma) for 4 h at 37ºC, followed
by removal of the culture medium and addition of 150 μl
dimethyl sulfoxide (Sigma). The absorbance was measured
at 570 nm, with 655 nm as the reference wavelength. All
experiments were performed in triplicate.
Colony formation assay
Cells were plated on a 6-well plate (0.5 × 103 cells per
well) and cultured for 10 days. The colonies were stained
with 1.0% crystal violet for 1 min after fixation with 10%
formaldehyde for 5 min. The experiment was performed
independently three times for each cell line.
Anchorage-independent growth ability assay
One thousand cells were trypsinized and suspended in
2 ml complete medium plus 0.33% agar (Sigma). The
agar-cell mixture was plated on top of a bottom layer
comprising 0.66% complete medium agar mixture. After
10 days, colony sizes were measured with an ocular mi-
crometer and colonies greater than 0.1 mm in diameter
were counted. The experiment was performed for inde-
pendently three times for each cell line.Flow cytometry analysis
All cells in a culture dish were harvested by trypsiniza-
tion, washed in ice-cold PBS, and fixed in 80% ice-cold
ethanol. Before staining, the cells were pelleted in a
cooled centrifuge and resuspended in cold PBS. Bovine
pancreatic RNAase (Sigma) was added at a final concen-
tration of 2 μg/ml, and cells were incubated at 37°C for
30 min, followed by incubation in 20 μg/ml propidium
iodide (Sigma) for 20 min at room temperature. 20,000
cells were analyzed on a flow cytometer (FACSCalibur;
BD Biosciences, Bedford, MA, USA).
Statistical analysis
Student’s t test was used to evaluate the significant dif-
ference of two groups of data in all the pertinent experi-
ments. A P value <0.05 (using a two-tailed paired t test)
was considered significantly different for two groups of
data.
Results
miR-208 expression is elevated in ESCC cell lines and
tissues
Real-time PCR analysis revealed that miR-208 expression
was markedly increased in all eleven ESCC cell lines, in-
cluding Kyse140, Kyse30, Kyse510, Kyse520, Eca109, TE-1,
Kyse410, Kyse180, EC18, HKESC1 and 108CA, compared
with that in NEEC (Figure 1A). Moreover, comparative ana-
lysis revealed that miR-208 was significantly overexpressed
in 10 pairs of cancerous tissues compared with the adjacent
noncancerous esophageal tissues (Figure 1B). Collectively,
these results suggested that miR-208 was upregulated in
ESCC.
Ectopic expression of miR-208 enhances proliferation of
ESCC cells
To investigate the effect of miR-208 on the development
and progression of ESCC, Kyse30 and Kyse410 ESCC cells,
which were with medium-level of miR-208 expression, sta-
bly overexpressing miR-208 were established (Figure 2A).
The MTT and colony formation assays showed that over-
expression of miR-208 dramatically increased the growth
rate of both ESCC cell lines compared with that of control
cells (Figure 2B and C). Importantly, the anchorage-
independent growth assay revealed that both Kyse30-
miR-208 and Kyse410-miR-208 cells showed more and
larger-sized colonies than their corresponding control
cells (Figure 2D). Moreover, we analyzed the cell cycle
of Kyse30-miR-208 and Kyse410-miR-208 cells by flow
cytometry, which showed a significant decrease in the
percentage of cells in G1/G0 phase and an increase in
the percentage of cells in S phase (Figure 2E). All these
results suggested that upregulation of miR-208 pro-
moted the proliferation and tumorigenicity of ESCC
cells.
Figure 1 Expression of miR-208 is increased in ESCC cell lines and tissues. A. Real-time PCR analysis of miR-208 expression in normal
esophageal epithelial cells (NEEC) and esophageal squamous carcinoma cells, including Kyse140, Kyse30, Kyse510, Kyse520, Eca109, TE-1, Kyse410,
Kyse180, EC18, HKESC1 and 108CA. Transcript levels were normalized using U6 expression. B. The expression of miR-208 was examined in 10
paired cancerous tissues (T) and their adjacent noncancerous esophageal tissues (ANT). The average miR-208 expression was normalized using U6
expression. Each bar represents the mean ± SD of three independent experiments. *P <0.05.
Li et al. Journal of Translational Medicine 2014, 12:196 Page 4 of 9
http://www.translational-medicine.com/content/12/1/196Inhibition of miR-208 reduces proliferation of ESCC cells
To further test whether endogenous miR-208 helps to
sustain the proliferative property of ESCC cells, loss-of-
function studies using a miR-208 inhibitor were used to
further investigate whether endogenous miR-208 helps
to maintain the proliferative properties of ESCC cells. As
shown in Figure 3A, B and C, suppression of miR-208
by transfection with the miR-208 inhibitor significantly
decreased the growth rate of both ESCC cell lines as com-
pared with that of NC transfected cells. The anchorage-
independent growth assay revealed that both Kyse30-miR-
208-inhibitor and Kyse410-miR-208-inhibitor cells formed
fewer and smaller-sized colonies than their corresponding
negative control cells, indicating the inhibitory function of
miR-208 inhibitor on ESCC tumorigenicity (Figure 3D).
Additionally, flow cytometry showed a significant increase
in the percentage of cells in G1/G0 phase and a decrease
in the percentage of cells in S phase in Kyse30-miR-208-
inhibitor and Kyse410-miR-208-inhibitor cells compared
with NC transfected cells (Figure 3E). These results sug-
gested that downregulation of miR-208 could suppress the
proliferation and tumorigenicity of ESCC cells.
SOX6 is a direct target of miR-208 in ESCC cells
A previous study showed that SOX6 is a tumor-suppressor
and plays an important role in ESCC progression [1].
Using publicly available algorithms (TargetScan, Pictar,
miRANDA), we found that SOX6 was a potential target
of miR-208 (Figure 4A). As predicted, western blotting
analysis revealed that SOX6 expression decreased in the
Kyse30 and Kyse410 ESCC cells ectopic expressing
miR-208 and increased in cells suppressing miR-208
(Figure 4B). To examine whether miR-208 mediated-
SOX6 downregulation was through the 3′-UTR of SOX6,
the SOX6- 3′-UTR fragment, containing three miR-208
binding sites, was subcloned into a pGL3 luciferase re-
porter vector. The results of the luciferase reporter assay
showed that overexpression of miR-208 decreased, andsuppression of miR-208 increased, the luciferase activity of
the SOX6 3′-UTR-luciferase reporter, whereas a miR-208
with mutated seed sequence failed to show an inhibitory
effect on the luciferase activity (Figure 4C). Meanwhile,
we observed that the mRNA of the SOX6 downstream
gene, p21 was significantly downregulated, and that of
Cyclin D1 was significantly upregulated, by miR-208
(Figure 4D). Moreover, the expression level of the p21
protein was downregulated, Cyclin D1 was upregulated,
and phosphorylated Rb was increased in miR-208 over-
expressing cells compared with the negative control
cells. In contrast, the expression level of p21 was upregu-
lated, Cyclin D1 was downregulated, and Rb phosphoryl-
ation was decreased in cells transfected with the miR-208
inhibitor (Figure 4E). Collectively, our results suggested
that SOX6 was a bona fide target of miR-208.
SOX6 suppression is critical for miR-208-induced cell
proliferation in ESCC
To investigate the effect of SOX6 reduction on ESCC
progression, we repressed endogenous SOX6 expression
using a SOX6-specific siRNA (Figure 5A). The MTT assay
and the colony formation assay both showed that silencing
SOX6 in miR-208 inhibitor transfected cells increased the
growth rate of the cells (Figure 5B and C). The anchorage-
independent growth assay showed similar results (Figure 5D).
All the results suggested that further silencing SOX6 ex-
pression in Kyse30-miR-208-inhibitor and Kyse410-miR-
208-inhibitor cells could reverse the inhibitory effect of
the miR-208 inhibitor on ESCC cells proliferation. These
data confirmed that miR-208 promoted ESCC cells prolif-
eration and tumorigenicity by repressing endogenous
SOX6 expression and that SOX6 plays important role in
miR-208-mediated cell proliferation.
Discussion
In the current study, we demonstrated that miR-208 is up-
regulated in ESCC cell lines and tissues. Overexpression
Figure 2 Upregulation of miR-208 promotes the proliferation ability of ESCC cells. A. Real-time PCR analysis of miR-208 expression in
Kyse30 and Kyse410 cells stably expressing miR-208 and in control cells. B. Effects of ectopic miR-208 on the proliferation of Kyse30 and Kyse410
cells lines analyzed by the MTT assay. C. Representative micrographs (left) and quantification (right) of crystal violet stained cell colonies formed
by the indicated ESCC cell lines, 10 days after inoculation. D. Effects of ectopic miR-208 on the tumorigenicity of Kyse30 and Kyse410 cell lines, as
determined by an anchorage-independent growth ability assay. Colonies larger than 0.1 mm were scored. E. Effects of miR-208 overexpression on
the cell cycle progression of ESCC cells measured by flow cytometry analysis. Each bar represents the mean ± SD of three independent
experiments. *P <0.05.
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of ESCC cells, probably through post-translationally
downregulating SOX6 expression by targeting its mRNA3′- UTR. The negative regulation of SOX6 by miR-208
leads to upregulation of p21, downregulation of cyclinD1,
and Rb phosphorylation. We demonstrated that miR-208
Figure 3 Inhibition of miR-208 reduces the proliferation of ESCC. A. Real-time PCR analysis of miR-208 expression in Kyse30 and Kyse410 cells
transfected with miR-208 inhibitor. B. The proliferation ability of ESCC cells Kyse30 and Kyse410 transfected with miR-208 inhibitor or NC measured by
the MTT assay. C. Representative micrographs (left) and quantification (right) of crystal violet stained cell colonies formed by indicated ESCC cell lines,
10 days after inoculation. D. The tumorigenicity of ESCC cells Kyse30 and Kyse410 transfected with miR-208 inhibitor or NC measured, as by an
anchorage-independent growth ability assay. Colonies larger than 0.1 mm were scored. E. Flow cytometry analysis of indicated ESCC cells transfected
with miR-208-inhibitor or NC. Each bar represents the mean ± SD of three independent experiments. *P <0.05.
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during ESCC progression.
Recent studies showed that miRNAs regulated various
cellular pathways by affecting the expression of multiple
target genes [8,20]. The expression of miRNAs mightcontribute to human carcinogenesis and cancer progres-
sion, and are considered as potential novel targets for
cancer diagnosis and therapy [21-24]. miR-208 has been
identified as a myomiR. It is specifically expressed at
much higher levels in cardiac tissue and is dysregulated
Figure 4 miR-208 directly targets the 3′-UTR of SOX6 mRNA. A. Schematic representation of the miR-208 target sites in the 3′-UTR of SOX6
mRNA and a miR-208 mutant containing two altered nucleotides in the seed sequence (miR-208-mut). B. The expression levels of SOX6 protein
in Kyse30 and Kyse410 cells overexpressing or suppressing miR-208, by western blotting 48 hours after transfection. α-Tubulin served as the
loading control. C. Luciferase assay of indicated cells transfected with the pGL3-SOX6-3′UTR reporter. D. Real-time PCR analysis of SOX6 downstream
genes mRNA expression in indicated ESCC cells. E. Expression of p21, CyclinD1, phosphorylated pRb, and Rb protein as measured by western blotting
in indicated ESCC cells. α-Tubulin served as the loading control. Each bar represents the mean ± SD of three independent experiments. *P <0.05.
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miR-208 improved cardiac function and patient survival
during heart failure [27,28]. However, the expression and
function of miR-208 in cancers remain unknown. For the
first time, we have demonstrated that miR-208 expression
is correlated with ESCC progression and might play an
important role during ESCC development. It has also beenreported that miR-208 downregulates the Ets1 proto-
oncogene, which is closely involved in the regulation of
cell proliferation, differentiation, metastasis, apoptosis,
and angiogenesis, by targeting the Ets1 mRNA 3′-UTR
[29]. Nevertheless, the expression level of miR-208 in
esophageal cancer or other cancers and its clinical rele-
vance, require further study.
Figure 5 miR-208 promotes ESCC progression by inhibiting SOX6. A. The expression levels of SOX6 in Kyse30-miR-208-inhibitor and
Kyse410-miR-208-inhibitor cells that were transfected with SOX6-siRNA, as measured by western blotting. α-Tubulin served as the loading control.
B. The growth rates in SOX6-silenced cells as indicated by the MTT assay. C. Representative micrographs (left) and quantification (right) of crystal
violet stained cell colonies formed by indicated ESCC cell lines 10 days after inoculation. D. Representative images (left) and quantification (right)
of colony numbers of indicated cells determined by an anchorage-independent growth assay. Colonies larger than 0.1 mm in diameter were
scored. Error bars represent mean ± SD from three independent experiments. *P < 0.05.
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regulation by miRNAs is highly sensitive to base pair mis-
matches within nucleotides 2–8 of the miRNA, which have
been defined as the seed region [30]. The functional
importance of seed region complementarity as the major
determinant of miRNA targeting has well established [31],
which the microRNAs with mutation in the seed se-
quences could not genetically match with target genes and
fail to inhibit the target genes expression [8,32]. In the
current study, we found that miR-208 negatively regulated
SOX6 expression by targeting SOX6 3′ untranslated
region (3′-UTR) in the sequence-specific manner. Consis-
tently, miR-208 with mutated seed sequence failed to
show an inhibitory effect on the luciferase activity of
SOX6. SOX6 is reported to have a tumor-suppressive
function in tumors [15,16]. SOX6 suppressed ESCC cells
proliferation and cell motility, and inhibited tumor forma-
tion. SOX6 also inhibits cell cycle G1/S phage transition
by upregulating p53 and p21WAF1/CIP1, and by downregu-
lating cyclin D1/CDK4, cyclin A and β–catenin [14,15]. In
our study, downregulation of SOX6 by miR-208 led to
downregulation of p21, upregulation of cyclin D1, andinduced phosphorylation of Rb, resulting in the promotion
of cell proliferation and cell cycle progression.
These data suggested that overexpression of miR-208
favored ESCC progression. Most patients with ESCC are
diagnosed at an advanced stage with lymph node (LN)
metastasis, resulting in a poor prognosis [33]. Therefore, a
better understanding of the development of LN metastasis
may lead to therapeutic improvements for ESCC patients.
SOX6 is closely associated with LN metastasis of ESCC
[15]. Whether miR-208 is involved in SOX6-associated LN
metastasis needs further study.
In summary, we describe, for the first time, that miR-208
plays an important role in ESCC development and progres-
sion. The results reveal that miR-208 is upregulated in
ESCC cell lines and tissues. Furthermore, miR-208 overex-
pression promotes cell proliferation and tumorigenicity in
human ESCC cell lines in vitro. Additionally, we identified
SOX6 mRNA as a direct and functional target of miR-208.
Finally, we revealed that SOX6 suppression is essential for
miR-208-induced cell proliferation in ESCC. Based on
these results, we propose that miR-208 might be used as a
therapeutic agent for ESCC. Further study is required to
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ESCC diagnosis and therapy.
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